- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02852239
Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment
A Phase I, Open Label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics of Dabrafenib in Healthy Subjects With Normal Renal Function and Subjects With Impaired Renal Function
Study Overview
Detailed Description
The main objective of this trial is to evaluate the pharmacokinetics of dabrafenib and metabolites after a single oral dose of dabrafenib in subjects with renal impairment as compared to healthy subjects with normal renal function.
This was a single-dose, open-label, parallel group single dose study to evaluate the pharmacokinetics (PK) and safety of a single oral dose of dabrafenib 100 mg in subjects with severe RI or ESRD compared to matched healthy subjects with normal renal function (control group).
The study consisted of a screening period, a treatment period and a follow-up period.
The Screening period started up to 28 days prior to dosing. Subjects who satisfied the inclusion/exclusion criteria at screening were admitted for baseline evaluations, which was done locally by the investigator. In the treatment period, subjects received a single 100 mg oral dose of dabrafenib administered as two 50 mg capsules with a whole glass of non-carbonated water (approximately 240 mL) in the morning of Day 1 following an overnight fast (minimum 10 hours). Subjects were confined to the study facility from Day -1 to Day 5, for collection of serial blood and urine samples. Subjects were discharged on Day 5.
In the follow-up period a telephone call was made to subjects 30 days post-dose to evaluate subject safety during the weeks after discharge from the facility. Adverse events occurring prior to Day 30 were followed until resolution or until judged to be permanent. Subjects returned to the clinic on Days 90 and 180 for the post-dose dermatological examination follow up.
For this study, the terms "investigational drug", "study drug" or "study treatment" refer to dabrafenib, administered as a single dose.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
DeBary, Florida, United States, 32713
- Omega Research Consultants LLC
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- Hassman Research Institute
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- Wake Research Associates Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All subjects:
- Females must be of non-childbearing potential or must have negative pregnancy results at screening
- Good health as determined by lack of clinically significant findings
- Subjects must have a BMI between 18.0 kg/m2 and 38.0 kg/m2, with a body weight of at least 50 kg and no more than 140 kg
- Vitals signs within normal range
- Laboratory values at screening within local normal ranges or considered non-clinically significant
Additional criteria for renal impairment subjects:
-Stable renal disease without evidence of renal progression in the past 28 days prior to dosing
Additional criteria for healthy matched subjects:
- Matched to at least 1 renal impairment subject by race, age (+/-10 years), gender and weight (+/-10%)
- An absolute GFR of at least 90 ml/min
Exclusion Criteria for all subjects:
- Significant acute illness within the two weeks prior to dosing
- History or current diagnosis of cardiac disease indicating significant risk such as uncontrolled or significant cardiac disease or clinically significant ECG abnormalities
- Subjects will be screened for drugs of abuse
- History of drug or alcohol abuse within 6 months prior to dosing or evidence of such abuse as indicated by laboratory values at screening or baseline.
- Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs.
- History of malignancy of any organ system, treated or untreated, within 5 years, regardless of where there is recurrence or metastases.
- Use of drugs known to prolong the QT interval within 4 weeks prior to dosing and for the duration of the study.
- Use of drugs know to affect CYP3A4 and/or CYP2C8 including both (strong or moderate) inhibitors and inducers, within 7 days prior to dosing or during the current study are prohibited
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 - Normal renal function
Subjects with normal renal function defined as GFR ≥ 90 mL/min at baseline and matching to the renal impaired subject based on gender, race, age, and weight.
|
Single dose dabrafenib 100 mg
Other Names:
|
Experimental: Group 2 - Severe renal function
Subjects with severe renal impairment defined as GFR of 15-29 mL/min at baseline.
|
Single dose dabrafenib 100 mg
Other Names:
|
Experimental: Group 3 - End stage renal disease (ESRD)
Subjects with end stage renal disease (ESRD), defined as GFR of <15 mL/min at baseline.
|
Single dose dabrafenib 100 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration (Cmax)
Time Frame: Predose through 96 hours postdose
|
The maximum (peak) observed plasma drug concentration after a single dose of dabrafenib
|
Predose through 96 hours postdose
|
Area under the curve (AUClast)
Time Frame: Predose through 96 hours postdose
|
AUClast is the area under the curve calculated to the last quantifiable concentration point after a single dose of dabrafenib
|
Predose through 96 hours postdose
|
Area under the curve (AUFinf)
Time Frame: Predose through 96 hours postdose
|
AUCinf is the area under the plasma concentration time curve extrapolated to infinity after a single dose of dabrafenib
|
Predose through 96 hours postdose
|
Systemic drug clearance (CL/F)
Time Frame: Predose through 96 hours postdose
|
Systemic clearance from plasma of dabrafenib after a single dose
|
Predose through 96 hours postdose
|
Time to reach maximum concentration (Tmax)
Time Frame: Predose through 96 hours postdose
|
The time to reach maximum (peak) concentration of dabrafenib after a single dose
|
Predose through 96 hours postdose
|
Terminal elimination rate (Lambda_z)
Time Frame: Predose through 96 hours postdose
|
Terminal elimination rate of dabrafenib after a single dose
|
Predose through 96 hours postdose
|
Elimination half-life (T1/2)
Time Frame: Predose through 96 hours postdose
|
Elimination half-life of dabrafenib after a single dose
|
Predose through 96 hours postdose
|
Volume of distribution (Vz/F)
Time Frame: Predose through 96 hours postdose
|
The apparent volume of distribution during the terminal elimination phase of dabrafenib after a single dose
|
Predose through 96 hours postdose
|
Unchanged drug excreted in urine (Aet)
Time Frame: Predose through 96 hours postdose
|
The amount of unchanged dabrafenib excreted in urine after a single dose
|
Predose through 96 hours postdose
|
Renal clearance (CLr)
Time Frame: Predose through 96 hours postdose
|
Renal clearance of dabrafenib calculated using plasma AUC after a single dose
|
Predose through 96 hours postdose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with adverse events
Time Frame: Time of drug administration through 30 days postdose
|
Assess the safety of a single dose of dabrafenib through AE reports of subjects from drug administration through 30 days postdose
|
Time of drug administration through 30 days postdose
|
Number of subjects with abnormal lab values related to study drug
Time Frame: Time of study drug administration through 30 days postdose
|
Assess the safety of a single dose of dabrafenib through hematology and chemistry blood tests
|
Time of study drug administration through 30 days postdose
|
Number of subjects with abnormal blood pressure related to study drug
Time Frame: Time of study drug administration through 30 days postdose
|
Assess the safety of a single dose of dabrafenib by monitoring changes in blood pressure
|
Time of study drug administration through 30 days postdose
|
Changes in electrocardiogram (ECG)
Time Frame: Time of study drug administration through 30 days postdose
|
Assess the safety of a single dose of dabrafenib by monitoring changes in ECG
|
Time of study drug administration through 30 days postdose
|
Number of subjects with abnormal pulse rate related to study drug
Time Frame: Time of study drug administration through 30 days postdose
|
Assess the safety of a single dose of dabrafenib by monitoring changes in heart rate
|
Time of study drug administration through 30 days postdose
|
Number of subjects with abnormal respiratory rate related to study drug
Time Frame: Time of study drug administration through 30 days postdose
|
Assess the safety of a single dose of dabrafenib by monitoring changes in respiratory rate
|
Time of study drug administration through 30 days postdose
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDRB436A2106
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Impairment
-
Eisai Inc.CompletedHepatic Impairment; Renal ImpairmentUnited States
-
JW PharmaceuticalCompletedHealthy, Renal ImpairmentKorea, Republic of
-
Kowa Research Institute, Inc.CompletedSevere Renal ImpairmentUnited States
-
Gilead SciencesTerminatedSevere Renal ImpairmentUnited States
-
Centre for Probe Development and CommercializationSt. Joseph's Healthcare Hamilton; McMaster UniversityCompleted
-
Sichuan Haisco Pharmaceutical Group Co., LtdThe First Affiliated Hospital of Zhengzhou UniversityCompletedChronic Renal ImpairmentChina
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy Subjects | Severe Renal ImpairmentCzechia
-
Melbourne HealthWithdrawnRenal Impairment After Cardiac SurgeryAustralia
-
Novartis PharmaceuticalsCompletedMild and Moderate Renal ImpairmentRussian Federation, Germany, Serbia
-
AstraZenecaCompletedRenal Impairment | Hepatic ImpairmentBulgaria
Clinical Trials on dabrafenib
-
Novartis PharmaceuticalsTerminated
-
Universitair Ziekenhuis BrusselCompleted
-
UNC Lineberger Comprehensive Cancer CenterGlaxoSmithKlineCompletedUnresectable Melanoma | Stage IV Melanoma | Stage III Melanoma | BRAF Mutant MelanomaUnited States
-
University Medical Center GroningenTerminated
-
GlaxoSmithKlineCompleted
-
Fondazione Melanoma OnlusWithdrawn
-
Novartis PharmaceuticalsRecruitingBRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid TumorJapan
-
Leiden University Medical CenterNovartisRecruitingAnaplastic Thyroid CancerNetherlands
-
Novartis PharmaceuticalsCompletedMalignant MelanomaPortugal
-
Spirita Oncology, LLCUniversity of ArizonaTerminatedBrain Metastases | Malignant MelanomaUnited States